Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
Subtype terms (2)
More specific conditions that are subtypes of Rhabdomyosarcoma in the MeSH hierarchy.
- Rhabdomyosarcoma, Alveolar
12 drugs (8 approved, 4 experimental)
- Rhabdomyosarcoma, Embryonal
12 drugs (8 approved, 4 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (3)
Phase 3 trials (11)
Phase 2 trials (96)
- s-methionine
- saracatinib
- methylprednisolone
- ly-3023414
- prexasertib
- dexrazoxane
- anlotinib
- allogeneic natural killer cells
- atezolizumab
- mk-1775
- olaparib
- sorafenib
- talazoparib
- bvd-523
- cd3-cd56+ natural killer cells
- cd40 ligand
- cixutumumab
- silmitasertib
- selinexor
- e7 peptide
- eribulin
- ef-1 peptide
- ef-2 peptide
- etanercept
- erdafitinib
- ganitumab
- vismodegib
- gemcitabine
- tacrolimus
- paclitaxel
- +66 more
Phase 1 trials (46)
- simvastatin
- F 18-fluoroazomycin arabinoside
- thalidomide
- abemaciclib
- afatinib
- autologous tumor infiltrating lymphocytes
- busulfan
- Iopofosine
- prednisone
- enoblituzumab
- pembrolizumab
- ribociclib
- lexatumumab
- mage-a1, mage-a3, and ny-eso-1 vaccine
- mocetinostat
- hsv-1716
- pexastimogene devacirepvec
- sirolimus
- stem cells
- cetuximab
- taladegib
- tanespimycin
- everolimus
- alemtuzumab
- vorinostat
- gefitinib
- neoantigen dna vaccine
- tumor associated antigen specific cytotoxic t lymphocytes
- tumor-pulsed dendritic cells
- sodium thiosulfate
- +16 more
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (22)
- National Cancer Institute (NCI)
- Children's Cancer and Leukaemia Group
- Cooperative Weichteilsarkom Study Group
- European Paediatric Soft Tissue Sarcoma Study Group
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
- Swiss Pediatric Oncology Group
- University of Padova
- University of Bristol
- Mayo Clinic
- Dutch Childhood Oncology Group
- Societe Internationale d'Oncologie Pediatrique (SIOP)
- University of Ulm
- University of Minnesota
- Institut Gustave Roussy
- University of Texas at Houston
- Childrens Hospital for Wales
- University of Tuebingen
- Deutsche Kinderkrebsstiftung
- Italian Association for Pediatric Hematology Oncology
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria
- The Swedish Childhood Solid Tumor Working Group
- Polish Paediatric Solid Tumours Study Group
Organization Involved with Phase 2 Indications (57)
- Daiichi Sankyo
- Eisai
- Celgene
- Bristol-Myers Squibb
- Imclone
- Eli Lilly
- Pfizer
- Novartis
- Bayer
- BioInvent International AB
- Oncurious NV
- National Institutes of Health (NIH)
- Baylor University
- Centre Leon Berard
- Cornell University
- Eastern Cooperative Oncology Group
- University of Washington
- Japan Rhabdomyosarcoma Study Group
- Katholieke Universiteit Leuven
- Kyoto Prefectural University of Medicine
- KK Women's and Children's Hospital
- Medical College of Wisconsin
- Oregon Health and Science University
- Sarcoma Alliance for Research through Collaboration
- Southwest Oncology Group
- University of Miami
- University of Michigan
- University of Milan
- University of South Florida
- University of Toronto
- +27 more
Organization Involved with Phase 1 Indications (28)
- Merckle
- AstraZeneca
- MacroGenics
- Mirati Therapeutics Inc.
- Teva
- Boehringer Ingelheim
- Case Western Reserve University
- Harvard University
- Duke University
- Emory University
- New York Medical College
- Ohio State University
- University of Louisville
- South Plains Oncology Consortium
- University of California, Los Angeles
- University of Chicago
- University of Cincinnati
- Sumitomo Dainippon
- Pennsylvania State University
- Methodist Cancer Center, Houston, Texas
- Cellectar, Inc
- University of Wisconsin
- Jennerex Inc.
- Children's National Medical Center
- CURE Childhood Cancer, Inc.
- Pierce Phillips Charity
- Phase One Foundation
- The University of Texas, Dallas
Organization Involved with Other Experimental Indications (2)